What's Happening?
The Coalition for Epidemic Preparedness Innovations (CEPI) and the Pasteur Network have signed a Memorandum of Understanding (MoU) to strengthen their collaboration on epidemic and pandemic preparedness. This partnership aims to enhance regional capacity
in vaccine research and development, clinical trials, biosafety, biosecurity, laboratory science, and manufacturing. The collaboration seeks to ensure equitable access to vaccines during future public health emergencies by combining CEPI's expertise in vaccine development with the Pasteur Network's strengths in global disease surveillance and research capacity, particularly in the Global South. The MoU outlines potential collaboration in areas such as epidemiology, laboratory research, clinical trials, biosecurity, and manufacturing, with a focus on advancing mRNA vaccine capabilities and scalable manufacturing networks.
Why It's Important?
This partnership is significant as it addresses the global need for rapid and equitable vaccine access during health emergencies. By enhancing regional capacities, the collaboration aims to reduce the impact of future epidemics and pandemics. The initiative supports the '100 Days Mission,' which seeks to develop vaccines against new threats within 100 days, potentially saving millions of lives. The partnership also aims to reduce fragmentation in research efforts and accelerate vaccine development pathways, which is crucial for timely responses to emerging health threats. This collaboration could lead to improved public health outcomes and strengthen global health security.
What's Next?
CEPI and the Pasteur Network plan to hold regular consultations to monitor progress and align on public health priorities. They will explore new opportunities for collaboration, particularly in vaccine design and mRNA technologies. The partnership will focus on building sustainable regional capacity and reinforcing scientific quality and operational resilience. Activities may include staff training, protocol standardization, and network-wide coordination. The collaboration will also explore emerging opportunities in vaccine design and multi-institute networks for manufacturing and clinical research, with a particular focus on institutions in Africa and other Global South regions.
